Actualités

The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share

RBC Bearings (RBC) delivered earnings and revenue surprises of +13.45% and +2.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Thursday night earnings split two of the biggest names in tech in completely opposite directions, and the reason behind the gap reveals exactly where the AI infrastructure boom is creating winners and where it is quietly crushing margins.

The stock-market selloff in July looks more like a stress test than a breaking point.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

The EV maker delivered 12,194 vehicles in the second quarter and now expects to sell 65,000 to 70,000 EVs in 2026

Mastercard (NYSE:MA) reported second-quarter 2026 results that exceeded its expectations, supported by continued consumer and business spending, cross-border activity and demand for its value-added services. On a non-GAAP, currency-neutral basis, net revenue rose 12% year over year, adjusted net in

AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The bitcoin treasury company reported an $8.32 billion unrealized markdown on its holdings as bitcoin traded well below its average purchase price

Enbridge (ENB) delivered earnings and revenue surprises of +6.98% and +95.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dominion Energy (D) delivered earnings and revenue surprises of +8.22% and +10.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Some Tesla executives have been told to prepare for a separation of the automaker's China business ahead of a potential merger with SpaceX, the Journal reports. The China business brought in $8.86 billion of sales in the first half of 2026, accounting for 17.

Ares Capital and Blue Owl Capital reported resilient second-quarter results this week, while Ares Management posted record fundraising, highlighting continued institutional demand for private credit despite rising defaults, ‌retail redemptions and liquidity concerns. Ares Management, one of the industry's largest players, raised a record $36 billion ‌in the second quarter, including $23.7 billion for its credit strategies. Assets under management rose 17% from a year earlier to $671.3 billion.

The electrical infrastructure supplier reported second-quarter earnings per share of $3.15, with sales of $8.5 billion. Wall Street was looking for EPS of $3.07 and sales of $8.2 billion.

Roblox Stock Drops. Revenue Is Strong, But Users and Bookings Disappoint

AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.

The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditional IPOs raising $114.1 billion through June 30, 2026 – roughly seven times the amount raised during the first half of 2025. SpaceX, the largest IPO in Wall Street history, understandably dominated the headlines and made Elon Musk the world’s first trillionaire, but the strength of the market extended well beyond a single blockbuster listing.Claim 55%

Novo Nordisk shares dropped after the Danish drugmaker said an experimental medicine didn't reduce risk of major adverse cardiovascular events in a late-stage trial. The company's Denmark-listed stock was down nearly 10%, while its American depositary receipts fell about 9% in premarket trading in New York.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

Moby summary of Altria Group, Inc.'s Q2 2026 earnings call

Moby summary of Intercontinental Exchange, Inc.'s Q2 2026 earnings call

Moby summary of Eversource Energy's Q2 2026 earnings call

Robinhood Markets (Nasdaq: HOOD) reported its earnings for the second quarter of 2026 on July 29. The brokerage platform, popular for its equity, crypto, and tokenized stock offerings, generated $1.31 billion in revenue and $0.62 in earnings per share (EPS), beating Wall ...

Adjusted earnings of $12 billion, or $6.06 per share, beat analyst estimates by 50 cents as higher oil and refining margins drove results

Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.

The e-commerce and cloud giant topped second quarter expectations as accelerating cloud growth at Amazon Web Services (AWS) helped drive strong results.

The e-commerce and cloud giant topped second quarter expectations as accelerating cloud growth at Amazon Web Services (AWS) helped drive strong results.

The company said refunds were limited because it stockpiled inventory ahead of tariffs and is not the importer of record for most goods in its store

Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial.